TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04623476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pathophysiological Excision for Crohn's disease
Description: Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
Study: NCT03506542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen
Description: Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacotrabeculectomy
Description: Trabeculectomy with cataract extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy
Description: Trabeculectomy with cataract extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
Study: NCT03718143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination AZD1775 with AraC
Description: AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination AZD1775 with AraC
Description: AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1775 only
Description: AZD1775 days 1-5 \& 8-12
Study: NCT00142883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill compared to pregabalin
Study: NCT01042080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory trigger (ET)
Description: Varying the cycling criterion according to the percentage of peak inspiratory flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory trigger (ET)
Description: Varying the cycling criterion according to the percentage of peak inspiratory flow
Study: NCT03546075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02441790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Active Range of Motion
Description: 3-9 days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Immobilization
Description: 21-27 days
Study: NCT03638505

Intervention type: OTHER
Intervention: PSP-QoL
Description: PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings.

Intervention type: OTHER
Intervention: PSP-QoL
Description: PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings.
Study: NCT01772615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Antibiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E. coli Nissle
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E. coli Nissle
Description: Probiotic
Study: NCT00527605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg capsule
Description: Dutasteride 0.5mg once daily orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride matched placebo
Description: Dutasteride matched placebo once daily orally
Study: NCT01348646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief intervention
Description: The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
Study: NCT03424447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: efferent limb stimulation
Study: NCT01316172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Cs
Description: education on consultation
Study: NCT01481311

Intervention type: DEVICE
Intervention: medical Body Composition Analyzer seca 514/515
Description: Current of 100 µA

Intervention type: DEVICE
Intervention: medical Body Composition Analyzer seca 514/515
Description: Current of 100 µA

Intervention type: PROCEDURE
Intervention: Deuterium and Sodium Bromide dilution methods
Description: Orally administered to the subject in a solution with 100 ml tap water.

Intervention type: PROCEDURE
Intervention: Deuterium and Sodium Bromide dilution methods
Description: Orally administered to the subject in a solution with 100 ml tap water.
Study: NCT02838849

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Fiber
Description: Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber and Water
Description: Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
Study: NCT03282760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Neural Stem Cells
Description: Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
Study: NCT00532480

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: 60 mg capsules
Study: NCT01748344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ONO-4053
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ONO-4053
Description: Experimental

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: None active
Study: NCT02490085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour intervention with multiple daily injections
Description: Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour intervention with closed-loop strategy
Description: Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Subject's usual insulin analog will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Subject's usual insulin analog will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump Accu-Chek Combo
Description: During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum
Description: In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum
Description: In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
Study: NCT01155115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum Collection
Description: Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum Collection
Description: Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exhaled Nitric Oxide
Description: The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exhaled Nitric Oxide
Description: The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
Study: NCT00794209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v fentanyl, AeroLEF
Description: * i.v fentanyl~* 5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~* 5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~* 5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~* 3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device.
Study: NCT05026788

Intervention type: OTHER
Intervention: type of treatment
Description: pathway of management for conservative treatment, operative treatment and type of anaesthesia used

Intervention type: OTHER
Intervention: type of treatment
Description: pathway of management for conservative treatment, operative treatment and type of anaesthesia used
Study: NCT02165384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear tube placement with the Hummingbird TTS
Description: Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
Study: NCT04753398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure Monitor, medication dispenser, telemonitoring technology
Description: The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
Study: NCT03340844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Touch (NT)
Description: Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Mesenteric Artery First (SMA)
Description: Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).
Study: NCT00687362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
Study: NCT02944448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 tablet 1 mg
Description: CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 tablet 2.5 mg
Description: CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 tablet 5 mg
Description: CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Study: NCT04086251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaido
Description: Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
Study: NCT02496949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: 600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
Study: NCT02471547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BWT with Mitomycin-C prior TURBT
Description: Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes
Study: NCT03468309

Intervention type: GENETIC
Intervention: Genecept Assay and G-DIG decision tool
Description: Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.
Study: NCT02317666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medication Review
Description: A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
Study: NCT04989582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The trauma recovery nursing intervention program
Description: The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
Study: NCT02250014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Undergo cryotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Undergo cryotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study: NCT02755272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion of 200 mg given on day one of each 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion of 800 mg/m\^2 given on days one and eight of each 21 day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion of 800 mg/m\^2 given on days one and eight of each 21 day treatment cycle.
Study: NCT02245828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QCC374
Description: Single and multiple ascending doses of QCC374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT00993707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX-100 (formerly ETX-100) (hyaluronic acid)
Description: 3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX-100 (formerly ETX-100) (hyaluronic acid)
Description: 3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTX-100 (formerly ETX-100) (hyaluronic acid)
Description: 3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort.
Study: NCT00540579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
Study: NCT01635114

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: 150 mg resVida per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks